Frontage Laboratories Executive and Leadership Team

Daniella Kranjac, the Co-Chief Executive Officer at Frontage Laboratories, directs the overarching corporate strategy and long-term growth initiatives. Focusing on the expansion of service capabilities, Kranjac aligns the organization with the evolving needs of biotechnology clients. This leadership role involves identifying strategic partnerships that enhance the drug development pipeline. By overseeing the integration of new service lines, the Co-Chief Executive Officer ensures the company maintains a competitive edge in the global CRO market. Daniella Kranjac also collaborates with the Board to refine the vision for preclinical and clinical service offerings. Through rigorous market analysis, the Co-Chief Executive Officer drives the adoption of innovative methodologies that support pharmaceutical clients in achieving development milestones. This executive leadership ensures that the organization remains a premier partner for complex molecule advancement across North American and international markets.

Zhongping Lin, the Co-Chief Executive Officer at Frontage Laboratories, manages the technical and scientific direction of the organization. By prioritizing the advancement of drug metabolism and pharmacokinetics, Lin ensures that the company delivers high-quality analytical testing and formulation development. This leadership role involves overseeing the scientific integrity of preclinical and clinical trial material manufacturing. Zhongping Lin also directs the expansion of bioanalytical capabilities to support diverse molecule development. Through the implementation of advanced safety and toxicology assessment protocols, the Co-Chief Executive Officer maintains compliance with international regulatory standards. This executive leadership fosters a culture of scientific excellence that enables biotechnology companies to navigate the drug discovery process successfully. By focusing on operational excellence and technical innovation, the Co-Chief Executive Officer secures the company's position as a leader in the global pharmaceutical services sector.

Huan Wang, the Interim Chief Financial Officer at Frontage Laboratories, manages the financial health and fiscal planning of the organization. By overseeing capital allocation and budgeting, Wang ensures that the company possesses the necessary resources to support drug discovery and development services. This leadership role involves monitoring financial performance across all service lines, including bioanalysis and preclinical safety assessments. Huan Wang also provides the strategic financial insights required for the Board to make informed decisions regarding growth and investment. Through the implementation of robust financial controls, the Interim Chief Financial Officer maintains transparency and fiscal discipline. This executive leadership supports the company's ability to advance a myriad of molecules through development. By optimizing the financial structure, the Interim Chief Financial Officer enables the organization to sustain its competitive position while delivering value to stakeholders and supporting the expansion of global operations.

Min Wang, the Chief Operating Officer at Frontage Laboratories, executes the daily operational strategies required to support integrated drug development services. Overseeing the efficiency of laboratory workflows, Wang ensures that analytical testing and bioanalysis projects meet strict timelines. This leadership role involves managing the resource allocation across preclinical and clinical trial material manufacturing facilities. Min Wang also coordinates with department heads to optimize the delivery of toxicology assessments. By streamlining internal processes, the Chief Operating Officer enhances the overall productivity of the organization. This executive leadership supports the company's mission by ensuring that operational capacity scales alongside client demand. Through the management of cross-functional teams, the Chief Operating Officer maintains high standards of quality and service delivery. Min Wang drives the operational infrastructure necessary to support the successful filing of regulatory submissions in the United States, China, and other global markets.

Abdul Mutlib, the Scientific Strategy Chief & Officer & President, Canada at Frontage Laboratories, directs the scientific vision and regional operations within the Canadian market. By architecting the strategic approach to drug metabolism and pharmacokinetics, Mutlib ensures that the company remains at the forefront of scientific innovation. This leadership role involves overseeing the integration of complex analytical testing services to support biotechnology clients. Abdul Mutlib also manages the expansion of the Canadian footprint, ensuring that regional operations align with the broader corporate mission. Through the development of specialized scientific protocols, the Scientific Strategy Chief & Officer & President, Canada enhances the company's capability to handle diverse molecule development. This executive leadership fosters collaboration between scientific teams to improve the quality of preclinical and clinical trial material manufacturing. By driving scientific excellence, the Scientific Strategy Chief & Officer & President, Canada supports the successful advancement of client projects through global regulatory submissions.